Monthly Archives: March 2012

lumigan eye lashes – Video

Posted on by

23-01-2012 16:43 link to online store pillsrx24.com lumigan eye lashes Lumigan eye drops contain the active ingredient Bimatoprost ophtalmic solution which is prostaglandin derivative. Bimatoprost Kris Aquino plays the role of "Celine" on ABS-CBN's newest primetime television series, "Kung Tayo'y Magkakalayo" premiering on January 18, 2010. Paradiso 2010 : Summer's Ultimate Outdoor and Dance Party ... >enterococcus faecalis resistance to cipro abilify for kids age 4 kihawiwa.100webspace.net/anti-acidity/EK9rl.html eli lilly cialis investors. Physician's Plan | Northern California Medical Weight Loss, Medical Weight Management, and Facial Aesthetics. Medical Weight Loss in Redding, Red Bluff. lumigan eye lashes mascara lumigan eye lashes

Read the original:
lumigan eye lashes - Video

Immortality Could Soon Be Reality? 2012 – Video

Posted on by

15-02-2012 19:06 Technologies today could allow the next generation to live up to 150, but how far should scientists go to allow people to live this long? More than just possible as some aging experts believe scientific breakthroughs will mean babies born today will live more than 100 years. Geriatrician Dr. Joyce Fogel says medical advances have already made a huge difference. "There was a time when people didn't live to older age because they died from the flu. We're doing much better. In 1900, when somebody was born, they were expected to live to the age of 50," she said. Scientists are making huge advances in the lab, growing new organs from adult human stem cells, creating body parts with 3D printers, and using gene therapy to successfully treat diseases like blindness and leukemia. And that's not all. Doctors have already doubled the lifespan of a worm. "The hope is that we could make a drug that would replicate in humans so that it would allow humans to stay young longer as well," Dr. Cynthia Kenyon said. ADG Facebook: http://www.facebook.com Follow ADG on Twitter: twitter.com

Read the original here:
Immortality Could Soon Be Reality? 2012 - Video

Canada’s murky legal world of surrogate-consultants and human-egg buyers

Posted on by

Struggling to make ends meet as a university English major, Elizabeth could not help but notice the online classified ad, offering healthy young women the potential to earn $5,000.

She jumped at the opportunity, even after discovering the work involved donating eggs for use in fertility treatment. The 22-year-old was told the money was to reimburse her for expenses and lost time at work or school, as stipulated by criminal law that bans paying egg or sperm donors commercial fees.

As it turns out, Elizabeth said she had no expenses to speak of and took off no time from school, yet the money came like clockwork the first $1,000 after she underwent various tests, the last $4,000 when the eggs were retrieved.

I was a broke student and the $5,000 price tag was very desirable, said the Vancouver Island resident, who asked that her last name be withheld. [But] I felt like one part on the production line to eventually create this child, which this family is paying thousands of dollars to essentially produce by artificial means.

The ad was placed by one of a handful of unusual brokers that recruit surrogate mothers and egg donors for the growing ranks of people longing to be parents, but unable themselves to give birth.

A rare RCMP investigation of the Ontario agency Ms. Sager worked with Canadian Fertility Consultants have put the spotlight on the surrogate-consultant market, commercial enterprises at the heart of a process that, officially at least, is not supposed to treat the ingredients of human reproduction as commodities.

The work can mean bringing together clients and wombs-for-loan located continents apart; the demand for surrogates is so strong, agencies offer gift certificates and cash incentives to those who recruit new mothers.

Some reportedly handle as many as 50 pregnant surrogates at a time.

Brokers charge thousands for the service, yet Canadian law prohibits payment beyond reimbursing expenses for the carriers and donors themselves, part of the legal grey zone that envelops the industry.

In fact, the Assisted Human Reproduction Act also says it is also illegal to accept consideration for arranging for the services of a surrogate mother or to offer or advertise to make such an arrangement.

Go here to read the rest:
Canada’s murky legal world of surrogate-consultants and human-egg buyers

AnMed Health Family Medicine Center names waiting room in honor of two former patients

Posted on by

The AnMed Health Family Medicine Center, the practice site for the AnMed Health Family Medicine Residency Program, recently honored two of its former patients by dedicating its waiting room in their honor. Edison Thomas and his wife, Gene, were patients at the Family Medicine Center for 25 years. The couple was always pleased with the care they received from family medicine residents and faculty. To express their gratitude, the Thomases left a portion of their estate - $63,172 - to the Family Medicine Center. Mr. Thomas's two sisters surprised the Family Medicine Center with a check in October. After renovations, the Family Medicine Center unveiled The Mr. and Mrs. Edison C. Thomas Waiting Room on Feb. 3, 2012. "What a wonderful gesture of appreciation this gift is to recognize the 36 years of family medicine training and compassionate patient care rendered at our program," said Dr. Stoney Abercrombie, director of the AnMed Health Family Medicine Residency Program. Every day patients have the opportunity to give back to AnMed Health in honor of the caregivers who made a difference in their life. To find out how, call the AnMed Health Foundation at 864.512.3477 and ask about the Grateful Patient program. To learn more about planned giving, go online to http://www.anmedhealth.org/ourfoundation.

Continued here:
AnMed Health Family Medicine Center names waiting room in honor of two former patients

Clothing Chemistry: Mixing two classes proves successful

Posted on by

Paris Cooperative High School teachers Angie Propst and Brett Block presented their students with a team-taught lesson crossing over their subject areas of Clothing and Chemistry to identify the fiber content of various types of fabric.

Propst, the creator of the lesson, wanted to further her Clothing classs existing investigation of fiber characteristics by adding a science inquiry component. Some of the fibers used were natural and others synthetic.

Students used the observable absorbency rate in dye and burn characteristics, together with an elimination chart, to determine each fabrics fiber content.

Students also observed how the burning is affected by treatment with a flame retardant made by Chemistry Club students in lab using boric acid and borax detergent.

Mixing this solution had to be done carefully due to the solubility of the boric acid. Aspects of solubility and supersaturated solutions were investigated by the Chemistry Club students.

This lesson promoted student to student learning as Chemistry and Clothing students were paired together. The importance of lab safety and the use of a controlled experiment were modeled by the Chemistry students. Clothing students shared the base knowledge used for deductive reasoning with the characteristics of synthetic fibers verses natural fibers and characteristics of weaves verses knits.

Due to the success of this lab, it will be incorporated into both the Advanced Chemistry and Clothing curricula.

Read more from the original source:
Clothing Chemistry: Mixing two classes proves successful

SHSU Forensic Chemistry Student Wins Award

Posted on by

Sam Houston State University forensic chemistry senior Brittany Winner, from Kingsville, is not only a winner in name, but also in deed as the recipient of the 2012 Society of Toxicology Pfizer Undergraduate Student Travel Award.

Pfizer selects five outstanding undergraduates in the nation each year who are presenting research at the organizations annual meeting to receive travel support and free registration for the meeting. This years conference is March 11-15 in San Francisco.

Awardees are selected based on the quality of a submitted poster abstract, personal statement, and an advisers supporting recommendation. The purpose of the award is to foster an interest in graduate studies in the field of toxicology.

Winner will have an opportunity to showcase her work along with a number of other students interested in toxicological research during the week. Winner researches the properties of cyanide and methods to encapsulate it in order to create an antidote against its deadly effects. Her interest in toxicology and cyanide arose from a mentorship with Ilona Petrikovics, professor of chemistry and Sam Houston States expert on the studies of cyanide.

She talked about her work with cyanide in class, and I found it really interesting so I asked if I could be involved, said Winner. Petrikovicss research on cyanide is an ongoing project funded by the U.S. Governments Department of Defense. The study focuses on methods to dissipate its effects on the general population in case of cyanide use in bio-terrorism and/or poisoning.

During the mentorship, the relationship between Winner and Petrikovics developed into a strong partnership.

We had weekly lab meetings that lasted about an hour. Outside the lab Id also just drop by and wed talk. We talked about the research and other aspects of life, Winner said.

At the conference, Winner will be presented with a plaque for her accomplishments during an awards ceremony. The conference also provides a range of opportunities for companies to view and come into contact with different types of research and scholars.

Its a great place for networking, Winner said.

Throughout the convention, she will have contact with many people and be able to attend Pfizer events. She will also be matched with a Pfizer scientist who will serve as a mentor for the conference. Winners research will be published in the conferences collection of research, where companies will be able to review her research and contact her for more information.

Read the rest here:
SHSU Forensic Chemistry Student Wins Award

Plandai Biotechnology, Inc. Files Revolutionary Patent for Increasing Absorption of Antioxidant Protection

Posted on by

SEATTLE, WA--(Marketwire -03/09/12)- Planda Biotechnology, Inc. (OTC.BB: PLPL.OB - News) Chief Executive Officer Roger Duffield, today announced that a patent application has been filed on the company's proprietary process for increasing the absorption of plant phytonutrients, especially antioxidants. The document, which was filed with the U.S. Patent Office on February 14, 2012, covers the process of treating live plant material in a CRS Hydrodynamic Process in order to increase absorption by the body and to efficiently transport and release the phytonutrients into cells. The inventors are Dr. Tom Matula and Mr. Roger Duffield.

According to the literature, live plant materials subjected to the CRS hydrodynamic process releases the phytonutrients and, through the process, alters the stereochemical structure by changing trans-isomers into the cis form, and/or by changing cis-isomers into the trans form. Phytonutrients, such as carotenoids (found in tomatoes) usually have a 95% trans-structure, whereas flavonoids (such as those found in green tea) usually have a 95% cis-structure. The CRS hydrodynamic process alters the isomeric properties of released phytonutrients and rearranges them to a ratio more readily absorbable by human tissue, which ideally has a 50/50 cis/trans isomer ratio.

The benefits of delivering high concentrate bioavailable phytonutrients allows the body to more efficiently absorb the active and stable nutrients and antioxidants. For example, green tea, which is rich in antioxidants critical for protecting white and red blood cells and boosting the body's immune system, is not readily absorbed in its natural state. According to published research, the average person needs to consume 8-10 cups of green tea in order to receive a clinical dose of the necessary gallate catechins. Even the green tea extracts currently on the market lack the necessary bioavailable properties necessary for maximum absorption.

Mr. Duffield commented, "The CRS hydrodynamic process is able to address the release of select plant phytonutrients to maximize the efficiency of absorption, opening up the multi-billion dollar health and wellness market. By protecting the process of increasing bioavailability with intellectuals, this allows the company to focus on bringing the first botanical products to market -- products that we believe will exhibit demonstrably better benefits than what is currently available to consumers."

About Planda Biotechnology, Inc.

Planda Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principal holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Original post:
Plandai Biotechnology, Inc. Files Revolutionary Patent for Increasing Absorption of Antioxidant Protection

Anatomy of a crash: Mock accident motivates teens

Posted on by

It's prom night for students at Community High School. Earlier this week, juniors and seniors witnessed a carefully orchestrated tableau, carried out by dozens of emergency and law enforcement personnel.

An annual tradition at many high schools, Prom Promise presents a graphic reminder to young drivers, through the use of staged accident scenes, of the dangers of driving while distracted or intoxicated.

'Tickets' issued

The storyline began several weeks ago as the Tennessee Highway Patrol ticketed Viking drivers for minor traffic offenses. So many, in fact, that Judge Charles Rich scheduled a court date in the school library to accommodate all the offenders.

Parents were required to attend court with their children on Wednesday, where Rich offered leniency. Charges would be dismissed if the group would agree to attend a safety class.

"The whole purpose behind this, it's prom time -- and the [highway patrol] can tell you, the last several years in this county, around this time of year ... we have lost one or more of our students here," said Rich.

Grim statistics

According to the THP, teen drivers account for more than 50,000 accidents each year in Tennessee, with fatalities occurring in over 200.

Once released from the mock court, students joined their peers just behind the school where an accident scene had been staged. The car and van selected for use had been wrecked in separate accidents involving Community students this year.

Horrific 'crash'

View original post here:
Anatomy of a crash: Mock accident motivates teens

'Grey's Anatomy's' Kevin McKidd, Chandra Wilson to Direct Again (Exclusive)

Posted on by

Getty Images

Kevin McKidd and Chandra Wilson

Grey's Anatomy stars Kevin McKidd and Chandra Wilson are returning to the director's chair.

The duo will each direct one of the remaining Season 8 episodes of the ABC medical drama, The Hollywood Reporter has learned exclusively.

McKidd -- who first stepped behind the camera last season and directed the sixth episode of the Shonda Rhimes drama this year -- is set to take the lead on Episode 21. Wilson, meanwhile, will mark her sixth time at the helm when she directs Episode 22 of Grey's 24-episode season.

STORY: 'Grey's Anatomy's' Kevin McKidd: Owen and Cristina Have 'Brushed A Lot Under the Carpet'

"In a way, it almost feels like there's more pressure the second time because people are going to cut you some slack the first time," McKidd told THR earlier this season of the experience. "But the second time people expect you to really know what you're doing, and you should."

STORY: Shonda Rhimes Talks 'Grey's Anatomy's' Live Musical Benefit

An airdate has not yet been determined for the episodes.

The duo join a growing cadre of stars who have stepped behind the camera for their respective series, including Parenthood's Peter Krause, Royal Pains' Mark Feuerstein and Mad Men's Jon Hamm, who will direct the long-awaited season premiere.

More:
'Grey's Anatomy's' Kevin McKidd, Chandra Wilson to Direct Again (Exclusive)

Kony 2012: The Anatomy Of A Viral Success

Posted on by

Funny thing about the internet: you cant smell anything on it, but certain stories sure can cause a stink.

Two days ago, we told you about the meteoric rise of the latest viral video, Kony 2012, that didnt make the rounds on the internet so much as it grabbed the internet by the eyeballs and forced everybody to look directly at it. In the four days since it was uploaded to YouTube, the video has amassed nearly 58 million views while viral news of it has no doubt permeated your Facebook and Twitter feeds.

The video, in the impossible case it that hasnt yet osmosis-ed itself into your brain from at least one kind of media outlet, was created and released by Invisible Children, an organization thats been trying for years to draw worldwide attention toward Ugandan warlord Joseph Kony and his Lords Resistance Army. The Lords Resistance army is a special breed of awful because, aside from being Konys personal army, its made up of kidnapped children-turned-soldiers responsible for horrors ranging from hacking apart victims bodies to using abducted girls as sex slaves.

At any rate, you can see how theres high emotional appeal that would likely resonate with most people containing even a sliver of sympathy. More, as with all things that finally have A Moment in the media, there is now the inevitable backlash against Kony 2012 criticizing Invisible Childrens approach.

So it goes.

Whats odd about Kony 2012s success, though, isnt that it went viral so quickly but rather why it went viral in the first place. Invisible Children has been trying to raise awareness about Kony since 2004 when the eponymous Invisible Children film was released, the groups first attempt to bring attention to Konys atrocities. Invisible Children have released 11 films in all yet this is the first one to truly achieve a viral, nigh-zeitgeist status. In fact, its taken Invisible Children so long to finally land a hit with their films that Joseph Kony isnt even in Uganda anymore (he reportedly left in 2006).

Some of the success has been attributed to Invisible Childrens goal of enlisting the help of culturemakers. Others have asserted that Kony 2012 succeeded due to clever marketing on social media. Both of these belie Invisible Childrens previous efforts by assuming such endorsements and technologies werent used to propel their videos into the limelight. For one, Lady Gaga endorses a ton of things but not nearly all of them catch on the way Kony 2012 has. She and others have got a magic, but its far from being a true Midas touch.

The most salient difference between Kony 2012s world and the world of Invisible Childrens previous videos, I believe, is something far more simple: timing. The towering success of the anti-SOPA movement, Planned Parenthood supporters organizing to turn back Susan G. Komens decision to de-fund the organization, or even the recent backlast that has sent supporters fleeing from Rush Limbaugh due to his misogynistic remarks about Sandra Fluke all have helped build and fortify the edifice of social medias power. It could be argued that Kony 2012 was a beneficiary of those previous campaigns that, one, established the social media political infrastructure, and two, demonstrated that it works.

As these movements cycle more regularly and enjoy an ever-quickening ascent-descent with the worlds favor, though, do we run the risk of diminishing the potency of the viral campaign-as-political device the more these campaigns happen? Im in no way saying that itll be Invisible Childrens fault were viral campaigns to falter in the future whatever your feelings about the groups methods, good on IC for finally getting the world to pay attention to how horrible Kony is but rather highlighting the fact that these viral campaigns seem to be happening an awful lot lately.

Indeed, you can have too much of a good thing and so I fear that, after eventually growing tired of the endless parade of Next Big Things from the internet, instead of catching wind of political campaigns that really deserve our attention, the public will begin to simply hold their breath until the trend passes along and disappears into the trunks of internet fads.

View post:
Kony 2012: The Anatomy Of A Viral Success

Movie Man: 'Anatomy of a Murder' is top courtroom drama

Posted on by

If youre looking for courtroom drama, you dont have to look far, with thousands of hours of Court TV, Law & Order reruns and plain-old courtroom news on your television.

But if youre looking for a truly great courtroom drama, one thats complex, funny, smart and surprising, you need to watch Anatomy of a Murder. Released way back in 1959 and featuring a one-of-a-kind cast, its no kidding the greatest courtroom drama ever made.

Based on a book by a Michigan Supreme Court judge (writing under a pseudonym), Anatomy of a Murder follows a small-town Michigan lawyer (James Stewart) as he defends a young lieutenant (Ben Gazzara) on murder charges. Where things get complicated is when Stewart examines the motive: Gazzara claimed he killed the local bar owner for raping his wife. But as Stewart gets to know the wife (Lee Remick), he begins to wonder if there was a rape or if, down deep, even Gazzara believes there was a rape.

Pretty adult stuff for 1959, and Anatomy of a Murder doesnt stop there. Theres much discussion over the word panties being used in the courtroom (again, scandalous stuff for 1959), but on a deeper level, Anatomy of a Murder hints that what really happened doesnt matter what matters is what the jury thinks happened. It might not be justice, but its the law.

Masterfully directed by Otto Preminger (a guy who loved pushing the envelope, content-wise), Anatomy of a Murder is full of elements that make it a classic film. The cast also includes a young George C. Scott as the big-city prosecutor, Eve Arden as Stewarts world-weary assistant, Orson Bean and Howard McNear (Floyd the barber from Andy Griffith) as expert witnesses and lawyer Joseph Welch, the man who brought down Sen. Joe McCarthy, as the judge. Whats more, not only does jazz legend Duke Ellington supply the music, he also has a cameo as Pie Eye, who for some reason is playing piano in a tiny Michigan tavern. That Michigan atmosphere, incidentally, is one of the movies biggest stars. Preminger filmed the movie in the Upper Peninsula, and it gives the film a feeling like no other Hollywood picture. Heck, even the opening credits iconic images created by legendary Saul Bass are memorable. Its just a great, great movie.

Thankfully, Criterions new edition does it justice. Besides a remastered print of the film, it includes footage from the set; segments on Ellington, Bass and Preminger; the trailer and more.

The Town

Someone at Warner Home Video must really love Ben Affleck.

I mean, The Town is a fine film, with solid direction and acting from Affleck and a strong supporting cast. But its not a classic though you wouldnt know that from the packaging of The Town Ultimate Collectors Edition. The boxed set includes multiple versions of the movie on Blu-ray and DVD, a feature-length documentary, a map of the Charlestown area of Boston, a folder full of files about the films characters, a hardcover book of photos from the set, a letter from Affleck and, believe it not, temporary tattoos exactly like the one Jeremy Renners character sports in the movie (and that you only see on-screen for a split second).

Quite a package for a movie thats pretty good but not great. I liked a lot of The Town, including the well-staged robberies and the simmering tension between the various thieves. But I thought it was another example of a movie let down by its ending, one that does right by its star but not by its main character. I dont want to spoil anything if you havent seen it because it is worth watching but the final scenes make no sense. The idea that the FBI would just quit surveilling the one person with a connection to their fugitive, then ignore the expensive and public! gift made in the name of that fugitives mom is ridiculous.

Here is the original post:
Movie Man: 'Anatomy of a Murder' is top courtroom drama

Kony 2012: The anatomy of a viral campaign

Posted on by

A particularly savvy media campaign by a nonprofit group called Invisible Children has pushed a debate about Uganda and rebel leader Joseph Kony into a very bright spotlight.

Without getting into the arguments about the political motivations of the nonprofit and the consequences of its campaign check out coverage from The Washington Posts Elizabeth Flock for more information on the situation and its history its astonishing that the groups members have been able to draw this much attention now to a conflict thats been going on since the 1980s.

So how did they do it?

The group launched a campaign called Kony 2012, an effort to raise awareness about Kony and the small force the Obama administration sent to Uganda in October with the intent of killing or capturing him and combating his Lords Resistance Army (LRA).

To get the campaign off the ground quickly, the group had users send messages to 20 culturemakers and 12 policymakers with influential Twitter accounts urging them to support the effort. The list included names such as U.N. Secretary General Ban Ki-moon, Republican presidential candidate Mitt Romney and former President George W. Bush, as well as celebrities such as Angelina Jolie, George Clooney, Mark Zuckerberg and Lady Gaga.

The message that users could send to those people included a hashtag, #Kony2012, that gave the Twitter community something to galvanize around. It read: Help us end #LRA violence. Visit kony2012.com to find out why and how. @rickwarren Join us for #KONY2012

The group also made a well-produced short film that encouraged people to use social media to raise awareness about the movement, which spread quickly over Vimeo and YouTube, where it has garnered more than 57 million views.

The video boils down this complicated issue into a simple one, with a compelling narrative that tugs on the heartstrings and prompts outrage. And it gives users an easy way to take action: Share the video, share the story and dont stop speaking up until they get the result they want.

The group was also able to tap into an already strong social media presence on Facebook and other sites to get the message out in a big, noticeable burst.

And it certainly has worked. The hashtags #stopkony and #kony2012 have been on the list of trending topics worldwide on Twitter ever since launched its campaign Tuesday. Its been a fixture on Googles list of trending topics, and even the debate over the groups methods and message have kept its message afloat.

Read more here:
Kony 2012: The anatomy of a viral campaign

Columbus Aesthetic and Plastic Surgery is Pleased to Welcome Dr. Christine Edwards as their Laser Skin Treatment …

Posted on by

Columbus, Ohio Cosmetic Practice welcomes laser skin treatment physician Dr. Christine Edwards.

Columbus, OH (PRWEB) March 08, 2012

As the Laser Physician at Columbus Aesthetic & Plastic Surgery, Dr. Edwards will focus on providing the latest advanced non-invasive, anti-aging & rejuvenative laser skin treatment options available to correct a multitude of common skin concerns for her Columbus patients including: Pigmented Lesions, Sun Damage (freckles, age spots), Vascular Lesions (small blood vessels) Acne, Skin Firmness, Poor Skin Tone and Texture, Rosacea, Skin Redness, Facial Veins, Spider Veins, Broken Capillaries, Deep and Mild Wrinkles, Surgical & Acne Scars, Actinic Keratoses and Pigment Irregularities.

Dr. Edwards is extremely talented and her ability to treat so many common skin issues truly enhances the level of care at Columbus Aesthetic & Plastic Surgery. It is an honor to welcome her as the newest member of our team, said Dr. Robert Heck.

Dr. Edwards is highly skilled and will use the latest in laser procedures including light based laser skin rejuvenation and skin resurfacing treatments in Columbus, OH with the most advanced available laser systems. Dr. Susan Vasko commented, With our assortment of laser treatments: Broadband Light (BBL, Photofacial), YAG treatments, MicroPeels, Profractional Treatments, and now skin tightening with SkinTyte II, Dr. Edwards will be able to truly enhance the level of treatment for the patients at Columbus Aesthetic & Plastic Surgery.

Dr. Christine Edwards, a native from Columbus, OH, completed her medical degree at the West Virginia University Medical Center. While in West Virginia, she gained valuable experience on many fronts including her time practicing Emergency Medicine at Monongalia General Hospital, a Level One Trauma Unit. She spent much of her time in West Virginia in emergency medicine treating patients who presented extremely delicate and difficult situations. She also worked as a Clinical Instructor of Emergency Medicine with the West Virginia University Hospital, where she found great joy in training and mentoring new doctors in Emergency Care. Dr. John Wakelin noted, Dr. Edwardss extensive training, coupled with her love of teaching has given her an incredible ability to connect with each and every patient, making their experience here a comfortable and personal one.

Dr. Edwards always wanted to use her skills in aesthetic medicine. She spent additional time training in advanced laser therapies around the country, including training at Harvard, prior to joining Columbus Aesthetic & Plastic Surgery Group. Dr. Edwards commented, It has always been dream to pursue my love of aesthetic medicine. The team at Columbus Aesthetic & Plastic Surgery has always been associated with the highest level of patient care and advanced cosmetic and reconstructive procedures. I believe that my skills complement what the surgical staff does so well. She continues, The laser technology at CAPS is second to none. And with the addition of SkinTyte II, loose skin from aging, post weight-loss, and pregnancy, can be tightened faster, and easier than before. We offer the most advanced technology to help all our patients achieve their desired outcome.

About Columbus Aesthetic and Plastic Surgery

Columbus Aesthetic and Plastic Surgery consists of four Ohio based board-certified plastic surgeons: Dr. Timothy Treece, Dr. Susan Vasko, Dr. Robert Heck and Dr. John Wakelin, as well as four full service Columbus Medical Spa locations and a certified laser treatment physician, Dr. Christine Edwards. We are dedicated to creating an enjoyable, stress-free and thoroughly rewarding experience for you from your initial consultation to your last post-operative visit. Our job is to help you realize your aesthetic dreams and to help enhance the confident, beautiful person you already are.

At Columbus Aesthetic and Plastic Surgery our goal is to make your cosmetic dreams a reality and we work to make that happen for each and every one of our patients.

Link:
Columbus Aesthetic and Plastic Surgery is Pleased to Welcome Dr. Christine Edwards as their Laser Skin Treatment ...

Discover New Treatments For Parkinson’s Disease

Posted on by

Nearly one million people in the United States are living with Parkinson's Disease. Although there is no cure, there are medications and surgical options that can help manage symptoms optimally.

Winthrop-University Hospital's Perspectives in Health series will offer a free seminar for the public, "Discover New Treatments for Parkinson's Disease," on Tuesday,

March 20, at 7:00 PM. The program will be held at Winthrop's Community Outreach Center, located at 101 Mineola Boulevard at the corner of Second Street in Mineola. The speakers, who are two leading experts in the field of Parkinson's, will provide information about the most advanced treatment options and will explain the evaluation process for treating the disease.

Nora L. Chan, MD, Director of the Movement Disorders Program at Winthrop, will discuss how to optimize the medical management of the disease, and address the nonmovement related issues of Parkinson's, such as problems with cognition, depression, fatigue, and sleep.

Brian Synder, MD, will explain surgical techniques, including deep brain stimulation (DBS), an innovative, sophisticated technology that targets regions deep within the brain to control motor symptoms. A question and answer period will be included in the program.

Attendees are asked to arrive at 6:45 PM for registration. Parking and the entrance are available in the rear of the building. Seating is limited and pre-registration is required. To reserve a space, please call (516) 663-8300.

For information on other programs at the Hospital, please call 1-866-WINTHROP, or visit http://www.winthrop.org/communityprograms.

Original post:
Discover New Treatments For Parkinson's Disease

Discover New Treatments For Parkinson's Disease

Posted on by

Nearly one million people in the United States are living with Parkinson's Disease. Although there is no cure, there are medications and surgical options that can help manage symptoms optimally.

Winthrop-University Hospital's Perspectives in Health series will offer a free seminar for the public, "Discover New Treatments for Parkinson's Disease," on Tuesday,

March 20, at 7:00 PM. The program will be held at Winthrop's Community Outreach Center, located at 101 Mineola Boulevard at the corner of Second Street in Mineola. The speakers, who are two leading experts in the field of Parkinson's, will provide information about the most advanced treatment options and will explain the evaluation process for treating the disease.

Nora L. Chan, MD, Director of the Movement Disorders Program at Winthrop, will discuss how to optimize the medical management of the disease, and address the nonmovement related issues of Parkinson's, such as problems with cognition, depression, fatigue, and sleep.

Brian Synder, MD, will explain surgical techniques, including deep brain stimulation (DBS), an innovative, sophisticated technology that targets regions deep within the brain to control motor symptoms. A question and answer period will be included in the program.

Attendees are asked to arrive at 6:45 PM for registration. Parking and the entrance are available in the rear of the building. Seating is limited and pre-registration is required. To reserve a space, please call (516) 663-8300.

For information on other programs at the Hospital, please call 1-866-WINTHROP, or visit http://www.winthrop.org/communityprograms.

Original post:
Discover New Treatments For Parkinson's Disease

QR Pharma Awarded Funding By Michael J. Fox Foundation To Test Posiphen As A Treatment For Parkinson’s Disease

Posted on by

BERWYN, PA.--(BUSINESS WIRE)--

QR Pharma, Inc. (QR) a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease, Parkinson's disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded the company $468,000 to conduct research for the development of Posiphen to treat PD. QR will collaborate with Robert Nussbaum, MD, Professor, Department of Medicine and Chief, Division of Medical Genetics at the University of California, San Francisco and Jack T. Rogers, PhD, Associate Professor Psychiatry (Neuroscience) at the Massachusetts General Hospital, Genetics and Aging Research Unit.

Mutations and overexpression of alpha-synuclein (a-SYN) have been shown to cause familial PD while genetic association studies indicate a-SYN is a key risk factor in sporadic PD. Evidence suggests that therapies that can reduce a-SYN expression may block its pathogenic actions and therefore be useful in treating PD. In vitro studies conducted at Massachusetts General Hospital demonstrate that Posiphen lowers a-SYN levels by inhibiting a-SYN translation.

To establish efficacy in PD, Posiphen will be tested in transgenic mice engineered by Dr. Nussbaum's group at UCSF that express mutant human a-SYN. These mice exhibit early gastrointestinal dysfunction at three-months and motor abnormalities later in life, mimicking what is found in PD patients. Studies will be conducted to test, among other things, Posiphen's ability to reverse these abnormalities to establish pre-clinical efficacy as a basis for future testing in humans.

"Our animal model is based on the initial work we did 15 years ago identifying alpha-synuclein as the first human gene which, when mutated, causes Parkinson disease," said Dr. Robert Nussbaum. "Our model recapitulates the early signs of the disease and is well suited to test therapies directed toward regulating alpha-synuclein expression either on the gene or on the protein level."

"Alpha-synuclein is a high-priority target for our Foundation, as there is evidence that it plays an important role in both genetic and idiopathic cases of PD," said Kuldip Dave, PhD, associate director of research programs at MJFF. "QR Pharma's drug Posiphen has been shown to block the synthesis of alpha-synuclein. By decreasing alpha-synuclein levels in the brain, Posiphen could potentially be a novel treatment for PD."

"We are pleased that The Michael J. Fox Foundation for Parkinson's Research sees the potential of Posiphen in the treatment of Parkinson's disease," said Maria Maccecchini, Chief Executive Officer of QR. "We look forward to working with the excellent research teams led by Dr. Nussbaum and Dr. Rogers."

About Posiphen . QR's lead Posiphen is a small orally active compound with high blood brain barrier permeability, which lowers levels of toxic protein aggregates. It targets the mRNA of a number of proteins that are overexpressed in several neurological disorders such as Alzheimer's disease, Parkinson's disease and Down syndrome. It is in clinical development as an oral treatment for Alzheimer's disease. Posiphen reduces the rate of synthesis of amyloid precursor protein (APP) in cell cultures, normal, transgenic and trisomic mice as well as in humans. Posiphen also inhibits the synthesis of tau and alpha-synuclein in mice and humans. These neurotoxic aggregating proteins induce dysfunction, neuroinflammation and lead to cognitive impairment and neurodegeneration.

About QR Pharma, Inc. Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer's disease (AD), Parkinson's disease (PD) and Down syndrome (DS). QR currently has three product development programs - Posiphen for early stage AD and PD and BNC for advanced AD. For more information on QR Pharma, please visit the company's website, http://www.qrpharma.com.

About The Michael J. Fox Foundation for Parkinson's Research. As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $285 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Now through December 31, 2012, all new and increased giving to The Michael J. Fox Foundation, as well as gifts from donors who have not given since 2010 or earlier, will be matched on a dollar-for-dollar basis with the $50-million Brin Wojcicki Challenge, launched by Sergey Brin and Anne Wojcicki.

Link:
QR Pharma Awarded Funding By Michael J. Fox Foundation To Test Posiphen As A Treatment For Parkinson's Disease

QR Pharma Awarded Funding By Michael J. Fox Foundation To Test Posiphen As A Treatment For Parkinson's Disease

Posted on by

BERWYN, PA.--(BUSINESS WIRE)--

QR Pharma, Inc. (QR) a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease, Parkinson's disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded the company $468,000 to conduct research for the development of Posiphen to treat PD. QR will collaborate with Robert Nussbaum, MD, Professor, Department of Medicine and Chief, Division of Medical Genetics at the University of California, San Francisco and Jack T. Rogers, PhD, Associate Professor Psychiatry (Neuroscience) at the Massachusetts General Hospital, Genetics and Aging Research Unit.

Mutations and overexpression of alpha-synuclein (a-SYN) have been shown to cause familial PD while genetic association studies indicate a-SYN is a key risk factor in sporadic PD. Evidence suggests that therapies that can reduce a-SYN expression may block its pathogenic actions and therefore be useful in treating PD. In vitro studies conducted at Massachusetts General Hospital demonstrate that Posiphen lowers a-SYN levels by inhibiting a-SYN translation.

To establish efficacy in PD, Posiphen will be tested in transgenic mice engineered by Dr. Nussbaum's group at UCSF that express mutant human a-SYN. These mice exhibit early gastrointestinal dysfunction at three-months and motor abnormalities later in life, mimicking what is found in PD patients. Studies will be conducted to test, among other things, Posiphen's ability to reverse these abnormalities to establish pre-clinical efficacy as a basis for future testing in humans.

"Our animal model is based on the initial work we did 15 years ago identifying alpha-synuclein as the first human gene which, when mutated, causes Parkinson disease," said Dr. Robert Nussbaum. "Our model recapitulates the early signs of the disease and is well suited to test therapies directed toward regulating alpha-synuclein expression either on the gene or on the protein level."

"Alpha-synuclein is a high-priority target for our Foundation, as there is evidence that it plays an important role in both genetic and idiopathic cases of PD," said Kuldip Dave, PhD, associate director of research programs at MJFF. "QR Pharma's drug Posiphen has been shown to block the synthesis of alpha-synuclein. By decreasing alpha-synuclein levels in the brain, Posiphen could potentially be a novel treatment for PD."

"We are pleased that The Michael J. Fox Foundation for Parkinson's Research sees the potential of Posiphen in the treatment of Parkinson's disease," said Maria Maccecchini, Chief Executive Officer of QR. "We look forward to working with the excellent research teams led by Dr. Nussbaum and Dr. Rogers."

About Posiphen . QR's lead Posiphen is a small orally active compound with high blood brain barrier permeability, which lowers levels of toxic protein aggregates. It targets the mRNA of a number of proteins that are overexpressed in several neurological disorders such as Alzheimer's disease, Parkinson's disease and Down syndrome. It is in clinical development as an oral treatment for Alzheimer's disease. Posiphen reduces the rate of synthesis of amyloid precursor protein (APP) in cell cultures, normal, transgenic and trisomic mice as well as in humans. Posiphen also inhibits the synthesis of tau and alpha-synuclein in mice and humans. These neurotoxic aggregating proteins induce dysfunction, neuroinflammation and lead to cognitive impairment and neurodegeneration.

About QR Pharma, Inc. Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer's disease (AD), Parkinson's disease (PD) and Down syndrome (DS). QR currently has three product development programs - Posiphen for early stage AD and PD and BNC for advanced AD. For more information on QR Pharma, please visit the company's website, http://www.qrpharma.com.

About The Michael J. Fox Foundation for Parkinson's Research. As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $285 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. Now through December 31, 2012, all new and increased giving to The Michael J. Fox Foundation, as well as gifts from donors who have not given since 2010 or earlier, will be matched on a dollar-for-dollar basis with the $50-million Brin Wojcicki Challenge, launched by Sergey Brin and Anne Wojcicki.

Link:
QR Pharma Awarded Funding By Michael J. Fox Foundation To Test Posiphen As A Treatment For Parkinson's Disease